2022 will be a year of accelerated reshuffle in the pharmaceutical industry

Since the beginning of the year, a large number of news about the cancellation of drug registration certificates have been continuously released
.
For example, on January 4th, the Yunnan Provincial Food and Drug Administration issued an announcement on the suspension of production.
After research by the Yunnan Provincial Drug Administration, it agreed to a pharmaceutical company to cancel the "Drug Production License"; on January 6, the Yunnan Provincial Food and Drug Administration once again Announcement was issued, and after reviewing compliance with laws and regulations, a pharmaceutical company was approved to cancel the "Drug Production License"; The company's "Drug Production License"
.
Behind the initiative of these pharmaceutical companies to cancel their drug registration certificates, the market competition in the pharmaceutical industry is intensifying, industry supervision is tightening, and the market reshuffle is accelerating
.
The industry predicts that 2022 will be a year of accelerated reshuffle in the pharmaceutical industry
.
Pharmaceutical industry (Photo source: PharmaNet) Innovative drug field: "Remove the fake and preserve the real" The innovative drug industry is subject to multiple resonances such as policies, talents, and capital, and the entire industry is showing a booming development trend
.
But at the same time, the industry is also facing more stringent requirements
.
For example, on July 2, 2021, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration announced the draft of the "Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented to Clinical Value" to encourage innovative anti-tumor drugs that are truly valuable Enter into clinical trials and apply for approval for listing, and guide the rational allocation of innovative R&D resources
.
Under this new policy, the innovative concept of innovative drugs is to remove the false and preserve the true, which means that a large number of pseudo-innovative "me-too" drugs will usher in a major reshuffle
.
The industry expects that the next "me-too" market will usher in a cooling down, and at the same time, the R&D capabilities of innovative drug companies will be put to the test
.
Not only the pharmaceutical field, but also medical devices, consumables and other fields are also facing the challenge of innovation and transformation
.
The industry pointed out that, especially under the normalization of centralized procurement, pharmaceutical equipment companies will accelerate their transformation towards innovation, and it is expected that small and medium-sized enterprises with weak R&D capabilities will accelerate their elimination
.
Traditional Chinese Medicine Industry: Strengthening Supervision The traditional Chinese medicine industry is continuously supported by national policies and is ushering in new opportunities
.
In 2021, especially since the end of the year, the Chinese medicine industry is very popular, but soon after the start of the new year, the industry has ushered in stricter supervision
.
On January 7, 2022, the State Food and Drug Administration issued the "Technical Guidelines for the Study of Samples for Toxicology Research of New Chinese Medicines (Trial)", which aims to guide and standardize the preparation and quality control of samples for toxicology research of new Chinese medicines for registration and application.
, preparation and other aspects of research and process management
.
With the release of the pilot guidelines, the industry expects that the supervision of the traditional Chinese medicine industry will be further strengthened, and some new traditional Chinese medicines that do not meet the requirements will be eliminated, but in the long run, it will be conducive to the sustainable and healthy development of the traditional Chinese medicine industry
.
3 million pharmaceutical agents: transformation is accelerated Days got tougher
.
However, this does not mean that the position of medical representative will not be eliminated
.
The industry pointed out that products including anti-tumor drugs and newly approved drugs still need pharmacokinetics
.
Judging from the recent conditions for the recruitment of pharmaceutical agents by major pharmaceutical companies, pharmaceutical companies pay more attention to the transmission of product information by pharmaceutical representatives and their sensitivity to the market, "especially in order to cooperate with the launch of innovative drugs, pharmaceutical companies will need more professional pharmaceutical representatives.
Come and share professional disease knowledge, drug use information, and patient management knowledge with doctors
.
" This also means that in the future, professional pharmaceutical agents can better meet the needs of pharmaceutical companies
.
Therefore, if the pharmaceutical agent wants to stay in the industry, it needs to continuously improve its professional ability in order to go further
.